Lirum Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Peter McDonald
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.1yrs |
| CEO ownership | 7.1% |
| Management average tenure | no data |
| Board average tenure | 1.3yrs |
Recent management updates
No updates
Recent updates
No updates
CEO
Peter McDonald (49 yo)
1.1yrs
Tenure
Mr. Peter Joseph McDonald, CFA, has been CEO, Interim Principal Financial and Accounting Officer at Lirum Therapeutics, Inc. since April 2023 and Joined in April 2023. He was the Director of Research and L...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | less than a year | no data | 0.18% $ 180.1k | |
| Independent Director | less than a year | no data | 0.41% $ 420.2k | |
| Chairman | no data | no data | 22.63% $ 23.1m | |
| Vice-Chairman | no data | no data | 19.74% $ 20.1m | |
| Independent Director | 1.5yrs | no data | 0.20% $ 204.1k | |
| Independent Director | 1.5yrs | no data | 0.41% $ 420.2k |
1.3yrs
Average Tenure
57yo
Average Age
Experienced Board: LRTX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.